How Long Has Wegovy Been on the Market?

Introduction

Finding a weight loss solution that actually works often feels like an endless cycle of trial and error. You may have heard about a specific medication called Wegovy® and wondered if it is a brand-new discovery or a tested medical option. At TrimRx, we believe that understanding the history of your healthcare options is the first step toward making an informed decision about your metabolic health, and our guide to how GLP-1 works for weight loss is a helpful place to start. Wegovy® has become a household name recently, but its journey to the pharmacy shelf involves years of clinical research and regulatory milestones. This article covers the official timeline of its market release, the history of its active ingredient, and how its availability has changed since its debut. We will help you understand where this medication fits into the broader history of weight management and how you can access personalized care today.

The Official FDA Approval Date

Wegovy® officially entered the United States market following its approval by the Food and Drug Administration (FDA) on June 4, 2021. This was a significant moment in the medical community. It represented the first time since 2014 that the FDA had approved a new class of medication for chronic weight management.

While June 2021 marks the birth of the brand name Wegovy®, the medication itself was not entirely unknown to doctors. The approval was specifically for adults with obesity or those who are overweight and have at least one weight-related condition, such as high blood pressure or high cholesterol. It is intended to be used alongside a reduced-calorie diet and increased physical activity.

Key Takeaway: Wegovy® was officially approved by the FDA for chronic weight management in June 2021, making it a relatively established option in the current weight loss landscape.

The History of the Active Ingredient: Semaglutide

To understand how long Wegovy® has been on the market, we must look at its active ingredient: semaglutide. Semaglutide is a medication that belongs to a class called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1. This is a hormone your body naturally produces in the gut. It helps regulate appetite and blood sugar levels.

The timeline for semaglutide is much longer than the timeline for the brand Wegovy®:

• 2017: The FDA first approved semaglutide under the brand name Ozempic®. This version was specifically for the treatment of Type 2 diabetes.
• 2019: An oral version of semaglutide, called Rybelsus®, was approved for Type 2 diabetes.
• 2021: The higher-dose injectable version was approved as Wegovy® for weight loss.

Because Ozempic® has been used since 2017, doctors have had several years to observe how semaglutide works in the human body. If you want a broader overview of the treatment process, how to order GLP-1 medications effectively is a useful related read. This history provides a wealth of data regarding safety and effectiveness that predates the weight-loss-specific branding.

Why the Approval Process Takes Years

You might wonder why a medication like Wegovy® takes so long to reach the public. The process is designed to ensure both safety and efficacy through rigorous clinical trials. Before the 2021 approval, semaglutide underwent a series of large-scale studies known as the STEP clinical trials. STEP stands for Semaglutide Treatment Effect in People with obesity.

These trials involved thousands of participants and lasted for over a year. Researchers needed to prove that the medication helped people lose a significant amount of weight compared to a placebo. They also had to document every side effect to ensure the benefits outweighed the risks. This clinical foundation is why the medication was able to transition from a diabetes treatment to a weight management tool.

The Rise in Popularity Since 2021

Even though the medication was approved in mid-2021, it did not become a cultural phenomenon immediately. Its popularity surged in late 2022 and throughout 2023. This surge was driven by social media discussions and news coverage of its effectiveness.

This rapid increase in demand led to significant supply challenges. Many patients found it difficult to fill their prescriptions at local pharmacies. This period of “shortage” changed how many people accessed the medication. It led to an increased interest in telehealth platforms and compounded options, which is why a free assessment quiz can be a practical next step for people exploring treatment.

Understanding Compounded Semaglutide

Because of the high demand and frequent shortages of branded medications like Wegovy®, many people now look toward compounded semaglutide. It is important to understand the difference between these options.

Compounded medications are prepared by a licensed pharmacist. They combine, mix, or alter ingredients to create a medication tailored to the needs of an individual patient. At TrimRx, we connect patients with licensed providers who may prescribe compounded semaglutide when appropriate.

Note: Compounded semaglutide is not FDA-approved. However, it is prepared in FDA-registered and inspected compounding pharmacies. These pharmacies follow strict quality standards to ensure patient safety.

If you are trying to figure out whether a prescription program is right for you, complete the free assessment quiz to see what personalized care may look like. Compounded versions often provide a way for patients to continue their treatment even when branded supplies are low. They also allow for more flexible dosing schedules under the guidance of a healthcare professional.

How Wegovy® Compares to Other Medications on the Market

The weight loss medication market has grown significantly since 2021. When Wegovy® first launched, its primary competitor was an older GLP-1 called Saxenda® (liraglutide). Saxenda® requires a daily injection, whereas Wegovy® is a once-weekly injection. The weekly schedule was a major factor in its rapid adoption.

In late 2023, another competitor entered the market: Zepbound® (tirazepatide). Tirzepatide is the active ingredient in Mounjaro®, which was approved for diabetes in 2022. Tirzepatide works on two hormone receptors instead of just one. For readers comparing options, why some people are not losing weight with tirzepatide offers a helpful look at plateaus and expectations. While Wegovy® has been on the market longer for weight loss, these newer options provide more choices for patients and their doctors.

What We Have Learned Since the Launch

Since Wegovy® has been on the market for several years, healthcare providers now have a better understanding of the patient experience. We have learned more about the common side effects and how to manage them.

Most side effects are related to the digestive system. This is because GLP-1 medications slow down how quickly your stomach empties. This process helps you feel full longer, but it can also lead to:

• Nausea
• Occasional vomiting
• Diarrhea or constipation
• Stomach pain

Providers have found that “titrating” the dose—starting very low and slowly increasing it over several months—helps the body adjust. This gradual approach is a hallmark of the personalized programs we support.

The Role of Telehealth in Accessing Treatment

The landscape of weight loss changed forever after the 2021 approval of Wegovy®. Before this, most people had to visit a specialist in person for weight management. Today, telehealth has made these treatments much more accessible.

Telehealth allows you to consult with a licensed professional from the comfort of your home. This is especially helpful for those who live in areas without obesity medicine specialists. Through our platform, we provide a streamlined process for medical evaluation. If you are ready to see whether you qualify, take the free assessment quiz to begin the process before you ever start a program.

Eligibility and Starting Your Journey

Even though Wegovy® has been available since 2021, it is not a “magic pill” or suitable for everyone. Medical guidelines are very specific about who should use these medications. Generally, they are intended for individuals with a Body Mass Index (BMI) of 30 or higher. They may also be prescribed for those with a BMI of 27 or higher if they have a weight-related health issue.

Starting the journey involves several steps:

Step 1: Complete an assessment. You begin by providing your health history and weight loss goals. At TrimRx, we use a free assessment quiz to help determine if our program is a fit for you.

Step 2: Consult with a provider. A licensed healthcare professional reviews your information. They may order lab work to check your metabolic markers. This step ensures the medication is safe for your specific body.

Step 3: Receive a personalized plan. If approved, your provider will determine the best starting dose. This plan is not just about the medication; it includes ongoing support to help you make lifestyle changes.

Step 4: Ongoing monitoring. Weight loss is a marathon, not a sprint. Regular check-ins allow your provider to adjust your dose and help you manage any side effects.

The Importance of Nutritional Support

As we have seen in the years since Wegovy® hit the market, medication is only one piece of the puzzle. When you eat significantly less, you must ensure that the food you do eat is nutrient-dense. Some patients experience fatigue or muscle loss if they do not prioritize protein and vitamins.

To support the body’s natural pathways, some individuals choose to use supplements. Options like GLP-1 Daily Support can help provide the essential nutrients the body needs during a weight loss journey. Weight Loss Boost is another option for people looking for added support while eating less.

Looking Toward the Future of Weight Management

The success of Wegovy® since 2021 has sparked a new era of research. Scientists are currently looking at even more effective versions of these medications. Some are being developed as daily pills rather than weekly injections. Others are targeting three different hormones at once.

The goal of this ongoing research is to make weight management more sustainable and personalized. We are moving away from a “one size fits all” approach and toward a medical model that respects the complexity of human metabolism.

Bottom line: While Wegovy® has been on the market for a few years, the science behind it has been decades in the making. This history provides a foundation of safety that allows for the personalized, telehealth-driven care models we see today.

Conclusion

Wegovy® has been on the market since June 2021, but its impact on how we view weight loss is much deeper than a few years of sales. It represents a shift toward treating obesity as a medical condition rather than a failure of willpower. By using the body’s own hormonal signals, medications like semaglutide offer a path toward sustainable health that many previously thought was impossible.

TrimRx was built on the mission of making this science-backed approach accessible and empathetic. We understand that every weight loss journey is personal. Our goal is to provide a transparent, medically supervised platform where you can find the support you need without the stress of waiting rooms or hidden fees. Whether you are interested in the clinical expertise of our providers or our targeted supplements, we are here to guide you toward a healthier lifestyle.

If you are ready to see if a personalized program is right for you, the next step is simple. Take our free health assessment quiz to begin your journey with our dedicated team of specialists.

FAQ

When was Wegovy approved by the FDA?

Wegovy® was officially approved by the FDA on June 4, 2021. It was approved specifically for chronic weight management in adults who meet certain BMI criteria. This approval followed years of clinical trials that proved its effectiveness and safety.

Is Wegovy the same thing as Ozempic?

Both medications contain the same active ingredient, semaglutide. However, Ozempic® was approved in 2017 for the treatment of Type 2 diabetes, while Wegovy® is approved at a higher dose specifically for weight loss. They are marketed under different names to reflect these different medical uses.

How long has the active ingredient in Wegovy been studied?

Semaglutide, the active ingredient, has been studied in clinical trials for over a decade. It was first approved for medical use in the United States in 2017. The extensive data from those years of use for diabetes helped inform the safety profile for its 2021 weight loss approval.

Why is it sometimes hard to find Wegovy in pharmacies?

Since its rise in popularity around 2022, there has been a significant surge in demand that exceeded the manufacturer’s production capacity. These supply chain issues have led to intermittent shortages. This is one reason why many patients look for alternative access points, such as compounded semaglutide through telehealth platforms.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.